NANOVIRICIDES, INC. Contracts & Agreements

Amendment to Line of Credit Agreement dated (Filed With SEC on September 27, 2024)

Extension of Employment Agreement with Anil Diwan effective July 1, 2024 (Filed With SEC on August 9, 2024)

Extension of Employment Agreement with Meeta Vyas effective July 1, 2024 (Filed With SEC on August 9, 2024)

At Market Issuance Sales Agreement by and between NanoViricides, Inc. and EF Hutton LLC (Filed With SEC on April 5, 2024)

Amendment to License Agreement between the Company and TheraCour, dated February 13, 2024 (Filed With SEC on February 16, 2024)

Line of Credit Agreement between the Company and Dr. Anil R. Diwan, dated November 13, 2023 (Filed With SEC on February 16, 2024)

Extension Agreement between the Company and Dr. Anil R. Diwan, dated February 12, 2024 (Filed With SEC on February 16, 2024)

Letter from TheraCour Pharma, Inc (Filed With SEC on February 16, 2024)

Extension to Employment Agreement with A. Diwan effective July 1, 2023 (Filed With SEC on October 13, 2023)

Extension to CFO Agreement with Meeta Vyas effective July 1, 2023 (Filed With SEC on October 13, 2023)

Deferred Expense Exchange Agreement between the Registrant and TheraCour effective July 19, 2023 (Filed With SEC on September 1, 2023)

Convertible Promissory Note between the Registrant and TheraCour, effective July 19, 2023 (Filed With SEC on September 1, 2023)

Form of Plan of Conversion (Filed With SEC on May 25, 2023)

License Agreement between the Company and Karveer (Filed With SEC on March 31, 2023)

Extension of Employment Agreement with Anil Diwan (Filed With SEC on October 11, 2022)

Coronavirus License Agreement with TheraCour Pharma, Inc (Filed With SEC on September 15, 2021)

Extension of Employment Agreement with Anil Diwan (Filed With SEC on September 15, 2021)

Form of Director Retainer Agreement (Filed With SEC on November 19, 2020)

At Market Issuance Sales Agreement by and between NanoViricides, Inc., B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc., dated... (Filed With SEC on August 3, 2020)

Underwriting Agreement with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. dated July 8, 2020 (Filed With SEC on July 13, 2020)

Form of Securities Purchase Agreement dated May 21, 2020 by and between NanoViricides, Inc. and certain purchasers (Filed With SEC on May 22, 2020)

Placement Agent Agreement, dated May 21, 2020 by and between among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc (Filed With SEC on May 22, 2020)

Director Retainer Agreement, dated as of May 15, 2020, between the Company and Mr. Rokita (Filed With SEC on May 19, 2020)

Form of Director Retainer Agreement (Filed With SEC on February 11, 2020)

Form of Settlement Agreement and Mutual Release (Filed With SEC on January 28, 2020)

Form of Exchange Agreement (Filed With SEC on January 28, 2020)

Form of Common Stock Purchase Agreement (Filed With SEC on January 28, 2020)

Underwriting with Aegis Capital Corp. dated January 21, 2020 (Filed With SEC on January 27, 2020)

Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on January 8, 2020)

Employment Agreement with M Vyas (Filed With SEC on January 8, 2020)

Form of Series A Conversion Waiver (Filed With SEC on January 8, 2020)

Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on January 7, 2020)

Employment Agreement with M Vyas (Filed With SEC on January 7, 2020)

Form of Series A Conversion Waiver (Filed With SEC on January 7, 2020)

Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on December 23, 2019)

Employment Agreement with M Vyas (Filed With SEC on December 23, 2019)

Form of Series A Conversion Waiver (Filed With SEC on December 23, 2019)

Open End Mortgage Note (Filed With SEC on December 19, 2019)

Open End Mortgage Deed (Filed With SEC on December 19, 2019)

Deferred Expense Exchange Agreement (Filed With SEC on December 19, 2019)

Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on December 17, 2019)

Employment Agreement with M Vyas (Filed With SEC on December 17, 2019)

Form of Series A Conversion Waiver (Filed With SEC on December 17, 2019)

Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on November 29, 2019)

Employment Agreement with M Vyas (Filed With SEC on November 29, 2019)

Form of Series A Conversion Waiver (Filed With SEC on November 29, 2019)

License Agreement with TheraCour Pharma, Inc (Filed With SEC on November 6, 2019)

Form of Underwriting Agreement (Filed With SEC on September 27, 2019)

Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock (Filed With SEC on September 27, 2019)

Form of Pre-Funded Warrant (Filed With SEC on September 27, 2019)

Form of Common Stock Purchase Warrant (Filed With SEC on September 27, 2019)

Form of Representatives Warrant (Filed With SEC on September 27, 2019)

Employment Agreement with M Vyas (Filed With SEC on September 27, 2019)

Form of Series A Conversion Waiver (Filed With SEC on September 27, 2019)

Director Retainer Agreement (Filed With SEC on June 10, 2019)

Form of Securities Purchase Agreement dated February 27, 2019 by and between NanoViricides, Inc. and certain purchasers (Filed With SEC on March 1, 2019)

Form of Common Stock Purchase Warrant (Filed With SEC on March 1, 2019)

Placement Agent Agreement, dated February 27, 2019, by and between NanoViricides. and Chardan Capital Markets, LLC (Filed With SEC on March 1, 2019)

Director Retainer Agreement (Filed With SEC on October 31, 2018)

A. Diwan Employment Agreement (Filed With SEC on July 23, 2018)

I. Taraporewala Employment Agreement (Filed With SEC on July 23, 2018)

A Diwan Employment Agreement (Filed With SEC on July 19, 2018)

Form of Warrant (Filed With SEC on May 4, 2018)

Confidential Separation Agreement and General Release (Filed With SEC on May 4, 2018)

CONVERSION AND SETTLEMENT AGREEMENT (Filed With SEC on February 13, 2017)

AGREEMENT OF PURCHASE AND SALE (Filed With SEC on January 7, 2015)

******************** (Filed With SEC on January 24, 2014)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 24, 2014)

COMMON STOCK PURCHASE WARRANT (Filed With SEC on January 24, 2014)

******************** (Filed With SEC on September 13, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on September 13, 2013)

COMMON STOCK PURCHASE WARRANT __________ (Filed With SEC on September 13, 2013)

First Amendmentto SECURITIESPURCHASE AGREEMENT (Filed With SEC on December 27, 2012)

CERTIFICATE OF DESIGNATION, RIGHTS ANDPREFERENCES OF SERIES C CONVERTIBLE PREFERRED STOCK OF NANOVIRICIDES, INC. (Continued) (Filed With SEC on July 2, 2012)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 2, 2012)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on June 29, 2012)

Amendment to Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on November 3, 2011)

Securities Purchase Agreement dated November 1, 2011 by and between NanoViricides, Inc. and Seaside 88, LP (Filed With SEC on November 3, 2011)

Underwriter Agent Agreement Amendment No. 1 (Filed With SEC on April 19, 2011)

Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on April 19, 2011)

Securities Purchase Agreement dated April 5, 2011 by and between NanoViricides, Inc. and Seaside 88, LP (Filed With SEC on April 19, 2011)

Amended Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on September 22, 2010)

Letter Agreement and Amendment with respect to Follow-On Offering pursuant to that certain Securities Purchase Agreement, dated as of May 11, 2010, by and between NanoViricides,... (Filed With SEC on September 22, 2010)

Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners & Co., LLC (Filed With SEC on May 12, 2010)

Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (Filed With SEC on May 12, 2010)

Securities Purchase Agreement dated May 11, 2010 by and between NanoViricides, Inc. and Seaside 88, LP (Filed With SEC on May 12, 2010)

Form of Subscription Agreement of June 2009 Unit Offering (Filed With SEC on October 5, 2009)

Form of Subscription Agreement of June 2009 Warrant Exercise Offering (Filed With SEC on October 5, 2009)

Form of Subscription Agreement (Filed With SEC on July 10, 2009)

Form of Common Stock Purchase Warrant (Filed With SEC on July 10, 2009)

Form of Subscription Agreement (Filed With SEC on August 29, 2008)

Form of Common Stock Purchase Warrant dated September 21, 2007 (Filed With SEC on August 29, 2008)

Form of Subscription Agreement to Exercise $2.50 Warrants (Filed With SEC on August 29, 2008)

Form of Subscription Agreement to Exercise $1.00 Warrants (Filed With SEC on August 29, 2008)

Form of Subscription Agreement (Filed With SEC on October 18, 2007)

Form of Common Stock Purchase Warrant dated September 21, 2007 (Filed With SEC on October 18, 2007)

Investor Subscription Agreement dated September 21, 2007 between NanoViricides, Inc. and DKR Saturn Event Driven Holding Fund Ltd (Filed With SEC on September 27, 2007)

Registration Rights Agreement dated September 21, 2007 between NanoViricides, Inc. and DKR Saturn Event Driven Holding Fund Ltd (Filed With SEC on September 27, 2007)

Form of Common Stock Purchase Warrant dated September 21, 2007 (Filed With SEC on September 27, 2007)

Category

Industry

Companies

Contracts

NANOVIRICIDES, INC. Contracts & Agreements